Werewolf Therapeutics, Inc. (HOWL): Price and Financial Metrics
GET POWR RATINGS... FREE!
HOWL Stock Price Chart Interactive Chart >
HOWL Price/Volume Stats
| Current price | $3.95 | 52-week high | $21.67 |
| Prev. close | $3.92 | 52-week low | $3.51 |
| Day low | $3.73 | Volume | 39,700 |
| Day high | $3.96 | Avg. volume | 234,196 |
| 50-day MA | $4.57 | Dividend yield | N/A |
| 200-day MA | $10.86 | Market Cap | 109.23M |
Werewolf Therapeutics, Inc. (HOWL) Company Bio
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It offers PREDATOR, a platform of protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients. The company's lead product candidates include WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. It also develops WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Latest HOWL News From Around the Web
Below are the latest news stories about Werewolf Therapeutics Inc that investors may wish to consider to help them evaluate HOWL as an investment opportunity.
Werewolf Therapeutics to Present at the SVB Leerink Global Healthcare ConferenceCAMBRIDGE, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that management will present at the SVB Leerink Global Healthcare Conference taking place virtually from February 14-18, 2022. Daniel J. Hicklin, Ph.D., President and Chief |
Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth PlansThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining... |
Werewolf Therapeutics to Present at the H.C. Wainwright Bioconnect ConferenceCAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that management will present at the H.C. Wainwright Bioconnect Conference, taking place virtually from January 10-13, 2022. Daniel J. Hicklin, Ph.D., President and Chief Exe |
Reid Leonard Sells 3,000 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) StockWerewolf Therapeutics, Inc. (NASDAQ:HOWL) COO Reid Leonard sold 3,000 shares of the businesss stock in a transaction that occurred on Wednesday, December 15th. The shares were sold at an average price of $13.41, for a total value of $40,230.00. The transaction was disclosed in a legal filing with the SEC, which is available through this [] |
Werewolf Therapeutics Added to the Nasdaq Biotechnology IndexCAMBRIDGE, Mass., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that it has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 20, 2021. |
HOWL Price Returns
| 1-mo | -11.24% |
| 3-mo | -44.83% |
| 6-mo | -72.74% |
| 1-year | -73.45% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -66.83% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...